Pipeline

BRY104

An oral peptide drug candidate in preclinical development.

  1. Preclinical
  2. IND-enabling
  3. Phase 1

Taming the Wild West

A generation of research grade peptides is being sold on anecdote directly to the consumer. Almost none has been through a randomized controlled trial. We think that’s the opportunity, not the obstacle. BRY104 is being developed under an IND, in an oral solid dose form.

Status

Preclinical development

Being developed under an IND, in an oral solid dose form

PLACEHOLDER — regulatory disclaimer for BRY104 to be supplied.

Other programs

BRY101

Phase 1b dose finding

NAD+ medical food. Phase 1b dose finding to support wound healing.

BRY102

Preclinical

Neurodegenerative disease. 505(b)(1) IND candidate in preclinical development.

BRY103

IND-enabling

Metabolic Modulator. 505(b)(2) candidate in IND-enabling studies.